Advertisement
Advertisement
Moderna, Inc. (MRNA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 142.85 |
| Open | 141.93 |
| Bid | 149.95 x 1200 |
| Ask | 150.23 x 1400 |
| Day's Range | 139.54 - 151.02 |
| 52 Week Range | 115.61 - 497.49 |
| Volume | |
| Avg. Volume | 5,948,093 |
| Market Cap | 59.644B |
| Beta (5Y Monthly) | 1.69 |
| PE Ratio (TTM) | 4.20 |
| EPS (TTM) | 35.72 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 219.33 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
10% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for MRNA
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Moderna, Inc.Analyst Report: Moderna, Inc.Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.RatingFair ValueEconomic Moat6 days agoMorningstar
- Yahoo Finance
How mRNA tech blew open the door of UPS's cold chain logistics business
mRNA blew open the door for more cold chain logistics business, helping UPS grow at twice the pace it had previously anticipated.
- MarketWatch
The U.S. bets billions of dollars on better COVID-19 boosters as it prepares for a spike in COVID-19 cases in the coming months
The U.S. is gearing up for another wave of COVID-19 infections in the fall and winter following a flurry of activity this week.
- Zacks
FDA Recommends Adding New Omicron Subvariants to COVID Boosters
In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
